IDEAYA Biosciences (IDYA) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental assessment is neutral, scoring 5.2/10. Strengths include high cash‑to‑market (Cash‑MV) and excellent inventory turnover, while revenue‑to‑market and PB‑ROE lag. Gross profit margin appears high but quality is low, yielding a balanced view.

Analysis Checks(6/10)

Revenue-MV

Value-3.51

Score1/3

Weight12.48%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value3024.43

Score3/3

Weight3.22%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.55%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score1/3

Weight-1.17%

1M Return-0.63%

PB-ROE

Value1.66

Score0/3

Weight8.33%

1M Return3.23%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.95%

1M Return-0.50%

Fixed assets turnover ratio

Value25.46

Score3/3

Weight2.13%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.57%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight35.13%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight14.70%

1M Return5.94%

Is IDYA fundamentally strong?

IDYA scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -10.92% ROE, -51.99% net margin, -25.09 P/E ratio, 2.79 P/B ratio, and 61.90% earnings growth, these metrics solidify its Netural investment rating.